American Society of Hirudotherapy

Conservative management of neonatal cerebral sinovenous thrombosis with coexisting thrombophilia.

Case report published in Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis (2018)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportDrug DevelopmentKhatri et al. · Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2018

Abstract

: Neonatal cerebral sinovenous thrombosis (CSVT) comprises approximately 50% of all pediatric-related CSVT. Although guidelines support anticoagulation in pediatric CSVT, the role of anticoagulation in neonatal CSVT remains controversial. This case report details the course of a neonate diagnosed with extensive CSVT and concurrent bilateral thalamic and intraventricular hemorrhage. Due to existing hemorrhage at the time of diagnosis, anticoagulation therapy was not administered. Despite coexisting protein C and antithrombin deficiency, CSVT resolved spontaneously, and neurodevelopmental follow-up after 13 years suggests a good prognosis. Although our case had a positive outcome, the association between the use of anticoagulation with concurrent hemorrhage and long-term outcome in neonatal CSVT has not been investigated in prospective studies to firmly guide optimum treatment. Current literature and guidelines for the treatment of neonatal CSVT are reviewed in this article. Until robust studies are available, expert opinion recommends anticoagulation in a stable neonate with CSVT.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsAnticoagulantsCerebral HemorrhageConservative TreatmentHumansInfant, NewbornSinus Thrombosis, IntracranialThrombophiliaTreatment Outcome

Summary

: Neonatal cerebral sinovenous thrombosis (CSVT) comprises approximately 50% of all pediatric-related CSVT. Although guidelines support anticoagulation in pediatric CSVT, the role of anticoagulation in neonatal CSVT remains controversial.

Why This Matters for Hirudotherapy

This case report details the spontaneous resolution of neonatal cerebral sinovenous thrombosis without the use of anticoagulation therapy, despite coexisting thrombophilia and hemorrhage. The study addresses the controversial use of systemic anticoagulants in neonates, which shares a broad thematic connection to the anticoagulant mechanisms utilized in hirudotherapy. It highlights the clinical complexities of managing blood clotting in vulnerable patient populations where standard pharmaceutical interventions carry significant risks. However, the article features absolutely no mention of leeches, hirudotherapy, or leech-derived substances, making it strictly a clinical vignette on conservative medical management.

Citation

Conservative management of neonatal cerebral sinovenous thrombosis with coexisting thrombophilia.

Khatri et al. · Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2018

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.